Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study.
Dechuang JiaoGuangyu LiHao DaiJia WangJiao ZhangYangyang HouXuhui GuoYajie ZhaoXilong GongZhenzhen LiuPublished in: The oncologist (2024)
Compared to HER2 (3+) BC, the limited effectiveness of neoadjuvant trastuzumab and pertuzumab therapy for HER2 (2+)/ISH+ BC is due to subtype heterogeneity. Reassessment of targeted therapy efficacy in patients with HER2 (2+)/ISH+ BC is essential.
Keyphrases
- rectal cancer
- early stage
- locally advanced
- epidermal growth factor receptor
- lymph node
- metastatic breast cancer
- randomized controlled trial
- systematic review
- single cell
- squamous cell carcinoma
- sentinel lymph node
- neoadjuvant chemotherapy
- clinical trial
- tyrosine kinase
- stem cells
- double blind
- bone marrow
- young adults
- clinical evaluation